Ciglitazone

Ciglitazone

SCHEMBL38185

CC1(COc2ccc(CC3SC(=O)NC3=O)cc2)CCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 1.00
CYP3A4 P08684 2/20 1.00
MAPT P10636 2/20 1.00
MEN1 O00255 1/20 1.00
ALDH1A1 P00352 1/20 1.00
TP53 P04637 1/20 1.00
CYP1A2 P05177 1/20 1.00
ALOX15 P16050 1/20 1.00
TSHR P16473 1/20 1.00
KMT2A Q03164 1/20 1.00
HSD17B10 Q99714 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
HRH3 Q9Y5N1 1/20 0.60
FFAR1 O14842 5/20 0.57
PPARA Q07869 2/20 0.57
PPARG P37231 9/20 0.55
PARP1 P09874 1/20 0.53
RXRA P19793 1/20 0.52
MPC2 O95563 2/20 0.51
CYP2C8 P10632 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ciglitazone SCHEMBL20125581 1.00 HPGD (1.00) HPGDCYP3A4MAPTMEN1ALDH1A1
Ciglitazone SCHEMBL20125576 1.00 HPGD (1.00) HPGDCYP3A4MAPTMEN1ALDH1A1
Ciglitazone SCHEMBL21582134 0.99 HPGD (0.98) HPGDCYP3A4MAPTMEN1ALDH1A1
Ciglitazone SCHEMBL3189397 0.99 HPGD (0.98) HPGDCYP3A4MAPTMEN1ALDH1A1
Ciglitazone SCHEMBL8498957 0.94 HPGD (0.89) HPGDCYP3A4MAPTMEN1ALDH1A1
Ciglitazone SCHEMBL6203612 0.92 HPGD (0.84) HPGDCYP3A4MAPTMEN1ALDH1A1
SCHEMBL11091437 0.89 CYP3A4 (0.81) HPGDCYP3A4MAPTMEN1ALDH1A1
SCHEMBL11088249 0.88 CYP3A4 (0.79) HPGDCYP3A4MAPTMEN1ALDH1A1
SCHEMBL12521714 0.88 HPGD (0.79) HPGDCYP3A4MAPTMEN1ALDH1A1
SCHEMBL11083961 0.88 CYP3A4 (0.78) HPGDCYP3A4MAPTMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 14525 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3841097-B1 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) 2026-05-20 EP claimed
EP-4683679-A1 METHOD FOR DIAGNOSING AND TREATING NIS-EXPRESSING CARCINOMAS AND METASTASES NUSKE, Andreas (DE) 2026-01-28 EP claimed
EP-3452041-B1 COMPOSITIONS AND METHODS FOR ADMINISTERING PPAR-GAMMA-AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) 2026-01-14 EP claimed
US-20250360215-A1 PHARMACEUTICAL COMBINATIONS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES YUH CHIOU HWA (US) 2025-11-27 US claimed
US-20250332101-A1 Composition CORDEIRO MARIA FRANCESCA (GB) 2025-10-30 US claimed
EP-4640701-A2 GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF Janssen Sciences Ireland Unlimited Company (IE) 2025-10-29 EP claimed
EP-4635505-A1 THERAPEUTIC AGENT FOR CHRONIC RESPIRATORY DISEASES The Jikei University (JP) 2025-10-22 EP claimed
US-20250281507-A1 METHODS OF TREATING NEPHROTIC SYNDROME THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN’S HOSPITAL 2025-09-11 US claimed
EP-3787631-B1 MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS UNIV EMORY (US) 2025-09-10 EP claimed
US-20250221962-A1 FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES TICURE LTD (IL) 2025-07-10 US claimed
US-5457109-A Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus WARNER-LAMBERT COMPANY (US) 1995-10-10 US claimed
WO-1995007697-A2 USE OF THIAZOLIDINEDIONE DERIVATIVES AND RELATED ANTIHYPERGLYCEMIC AGENTS IN THE TREATMENT OF DISEASE STATES AT RISK FOR PROGRESSING TO NONINSULIN-DEPENDENT DIABETES MELLITUS WARNER-LAMBERT COMPANY (US) 1995-03-23 WO claimed
WO-1995007694-A1 USE OF THIAZOLIDINEDIONES TO PREVENT OR DELAY ONSET OF NIDDM SANKYO COMPANY, LIMITED (JP) 1995-03-23 WO claimed
US-5356913-A Use of insulin sensitizing agents to treat hypertension THE UPJOHN COMPANY (US) 1994-10-18 US claimed
EP-0514452-B1 USE OF INSULIN SENSITIZING AGENTS TO TREAT HYPERTENSION THE UPJOHN COMPANY (US) 1993-08-18 EP claimed
EP-0514452-A1 USE OF INSULIN SENSITIZING AGENTS TO TREAT HYPERTENSION. UPJOHN CO (US) 1992-11-25 EP claimed
WO-1991012003-A1 USE OF INSULIN SENSITIZING AGENTS TO TREAT HYPERTENSION THE UPJOHN COMPANY (US) 1991-08-22 WO claimed
EP-0008203-B1 THIAZOLIDINE DERIVATIVES, PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME Takeda Chemical Industries, Ltd. (JP) 1982-08-25 EP claimed
US-4287200-A USEFUL AS REMEDIES FOR DIABETES AND HYPERLIPEMIA TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1981-09-01 US claimed
EP-0008203-A1 Thiazolidine derivatives, preparing same and pharmaceutical compositions comprising same Takeda Chemical Industries, Ltd. (JP) 1980-02-20 EP claimed